+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neoantigen Targeted Therapies Market by Therapy Modality, Treatment Approach, Route of Administration, Age Group, Target Disease Indication, End-User - Global Forecast to 2030- Product Image
Neoantigen Targeted Therapies Market by Therapy Modality, Treatment Approach, Route of Administration, Age Group, Target Disease Indication, End-User - Global Forecast to 2030- Product Image
Sale

Neoantigen Targeted Therapies Market by Therapy Modality, Treatment Approach, Route of Administration, Age Group, Target Disease Indication, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896728
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Neoantigen targeted therapies are reshaping the landscape of precision oncology. These advances, which leverage patient-specific mutations to enhance immune response in cancer, represent a significant evolution for pharmaceutical, biotech, and healthcare leaders focused on improving personalized treatment outcomes while navigating complex regulatory and market dynamics.

Market Snapshot: Neoantigen Targeted Therapies Market

The Neoantigen Targeted Therapies Market experienced significant growth, expanding from USD 4.57 billion in 2024 to USD 5.30 billion in 2025. It is projected to maintain strong momentum with a CAGR of 16.16%, reaching USD 11.24 billion by 2030. Market performance is underpinned by rising demand for precision immunotherapy, greater adoption of genomic profiling, and increasing investment in clinical translation of personalized cancer solutions across key geographies.

Scope & Segmentation of Neoantigen Targeted Therapies

  • Therapy Modality: Adoptive Cell Therapy, Personalized Neoantigen Vaccines
  • Adoptive Cell Therapy: CAR-T Cell Therapy, T Cell Receptor (TCR) Therapy, Tumor-infiltrating Lymphocytes (TIL)
  • Personalized Neoantigen Vaccines: Dendritic Cell (DC) Vaccines, DNA/RNA-based Vaccines, Peptide (SLP) Vaccines
  • Treatment Approach: Combination Therapy, Monotherapy
  • Route of Administration: Oral, Parenteral (Intramuscular, Intravenous, Subcutaneous)
  • Age Group: Adult, Geriatric, Pediatric
  • Target Disease Indication: Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma
  • End-User: Academic & Government Research Institutes, Hospitals & Clinics, Specialty Clinics
  • Region Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Saudi Arabia, South Africa, and others), Asia-Pacific (including China, India, Japan, South Korea, Singapore, Australia, and additional strategic markets)
  • Key Companies Covered: Achilles Therapeutics, Agenus, AstraZeneca, BioNTech, Bristol-Myers Squibb, CureVac, Eli Lilly, EpiVax, F. Hoffmann-La Roche, Genentech, Genocea Biosciences, Gilead Sciences, GlaxoSmithKline, Gritstone bio, Immatics, Immunomic Therapeutics, IOVANCE Biotherapeutics, Medigene, Merck & Co., Moderna, Neon Therapeutics, Nykode Therapeutics, Pfizer, Precision Biologics, Valo Therapeutics

Key Takeaways for Senior Decision-Makers

  • Neoantigen targeted therapies market advances are driven by the application of advanced bioinformatics, genomics, and machine learning to enable precise targeting of patient‑specific mutations.
  • Adoptive cell therapy and bespoke vaccine modalities are rapidly maturing, strengthening strategic integration between academic research, large pharmaceutical firms, and emerging biotech innovators.
  • Combination therapy protocols that join neoantigen platforms with checkpoint inhibitors are establishing new clinical standards, increasing durability of patient response and broadening potential indications.
  • End-user adoption is expanding, as hospitals, clinics, and research institutes adapt infrastructure and capabilities to accommodate more complex, individualized immunotherapy delivery models.
  • Regionally, the Americas maintain a leadership position in clinical trials and manufacturing, while Asia-Pacific and parts of EMEA are accelerating their biopharma investments and trial participation to foster local expertise and capacity.
  • Ongoing education for both healthcare providers and payers is vital for driving reimbursement and uptake, directly influencing future access and adoption rates.

US Tariffs: Impact on Supply Chain and Cost Structure

New US tariffs instituted in 2025 have affected the sourcing and supply chains associated with neoantigen targeted therapies. Increased import duties on peptides, reagents, and specialized manufacturing equipment have prompted companies to diversify supplier networks and explore domestic production. Biotech firms are forging new manufacturing partnerships and adjusting pricing structures to offset cost increases, with some relocating production to exempt regions. These shifts may incentivize further onshoring and greater vertical integration, supporting a more resilient and agile supply chain environment.

Methodology & Data Sources

This report employs a rigorous, multidimensional approach that blends primary and secondary data collection. In-depth interviews with subject matter experts and key industry stakeholders inform qualitative findings, while peer-reviewed literature and industry reports supply robust quantitative analysis. Method validation and peer review ensure actionable insights and high confidence in the data presented.

Why This Report Matters

  • Supports strategic decision-making by delivering a comprehensive analysis of competitive, regulatory, and market-shaping factors specific to neoantigen targeted therapies.
  • Enables executive teams to identify high-impact opportunities for partnerships, technology investment, and market expansion—across clinical, operational, and commercial priorities.
  • Facilitates forward planning in response to evolving tariffs, supply chain complexities, and global regulatory requirements influencing the market’s future trajectory.

Conclusion

Neoantigen targeted therapies are driving significant changes in cancer care and biopharmaceutical innovation. Senior leaders who act on these insights are positioned to leverage new technologies and partnerships for sustainable growth in an evolving oncology landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neoantigen Targeted Therapies Market, by Therapy Modality
8.1. Introduction
8.2. Adoptive Cell Therapy
8.2.1. CAR-T Cell Therapy
8.2.2. T Cell Receptor (TCR) Therapy
8.2.3. Tumor-infiltrating lymphocytes (TIL)
8.3. Personalized Neoantigen Vaccines
8.3.1. Dendritic Cell (DC) Vaccines
8.3.2. DNA/ RNA-based Vaccines
8.3.3. Peptide (SLP) Vaccines
9. Neoantigen Targeted Therapies Market, by Treatment Approach
9.1. Introduction
9.2. Combination Therapy
9.3. Monotherapy
10. Neoantigen Targeted Therapies Market, by Route of Administration
10.1. Introduction
10.2. Oral
10.3. Parenteral
10.3.1. Intramuscular
10.3.2. Intravenous
10.3.3. Subcutaneous
11. Neoantigen Targeted Therapies Market, by Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Neoantigen Targeted Therapies Market, by Target Disease Indication
12.1. Introduction
12.2. Bone Cancer
12.3. Colorectal Cancer
12.4. Gynecological Cancer
12.5. Non-Small Cell Lung Cancer
12.6. Renal Cell Carcinoma
13. Neoantigen Targeted Therapies Market, by End-User
13.1. Introduction
13.2. Academic & Government Research Institutes
13.3. Hospitals & Clinics
13.4. Specialty Clinics
14. Americas Neoantigen Targeted Therapies Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Neoantigen Targeted Therapies Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Neoantigen Targeted Therapies Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Achilles Therapeutics Limited
17.3.2. Agenus Inc.
17.3.3. AstraZeneca plc
17.3.4. BioNTech SE
17.3.5. Bristol-Myers Squibb Company
17.3.6. CureVac N.V.
17.3.7. Eli Lilly and Company
17.3.8. EpiVax, Inc.
17.3.9. F. Hoffmann-La Roche AG
17.3.10. Genentech, Inc.
17.3.11. Genocea Biosciences, Inc.
17.3.12. Gilead Sciences, Inc.
17.3.13. GlaxoSmithKline plc
17.3.14. Gritstone bio, Inc.
17.3.15. Immatics N.V.
17.3.16. Immunomic Therapeutics, Inc.
17.3.17. IOVANCE Biotherapeutics, Inc.
17.3.18. Medigene AG
17.3.19. Merck & Co., Inc.
17.3.20. Moderna, Inc.
17.3.21. Neon Therapeutics, Inc.
17.3.22. Nykode Therapeutics
17.3.23. Pfizer Inc.
17.3.24. Precision Biologics
17.3.25. Valo Therapeutics Ltd
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. NEOANTIGEN TARGETED THERAPIES MARKET MULTI-CURRENCY
FIGURE 2. NEOANTIGEN TARGETED THERAPIES MARKET MULTI-LANGUAGE
FIGURE 3. NEOANTIGEN TARGETED THERAPIES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NEOANTIGEN TARGETED THERAPIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY T CELL RECEPTOR (TCR) THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES (TIL), BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL (DC) VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA/ RNA-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEPTIDE (SLP) VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 62. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 63. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 64. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 65. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 67. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 68. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 69. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 71. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 72. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 73. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 74. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 76. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 78. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 117. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 118. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 119. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 120. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 122. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 123. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 124. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 126. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 127. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 128. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 129. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 131. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 133. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 144. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 145. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 146. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 147. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 149. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 150. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 151. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 153. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 154. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 155. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 156. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 158. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 160. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 189. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 190. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 191. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 192. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 194. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 196. DENMARK NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 207. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 208. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 209. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 210. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 212. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 214. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 216. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 217. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 218. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 219. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 221. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 222. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 223. FINLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 242. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 243. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 244. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 245. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 246. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 248. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 249. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 250. EGYPT NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 252. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 253. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 254. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 255. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 257. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 258. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 259. TURKEY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 270. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 271. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 272. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 273. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 275. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 277. NORWAY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 278. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 279. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 280. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 281. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 282. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 284. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 286. POLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC NEOANTIGEN

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Neoantigen Targeted Therapies market report include:
  • Achilles Therapeutics Limited
  • Agenus Inc.
  • AstraZeneca plc
  • BioNTech SE
  • Bristol‑Myers Squibb Company
  • CureVac N.V.
  • Eli Lilly and Company
  • EpiVax, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Genocea Biosciences, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Gritstone bio, Inc.
  • Immatics N.V.
  • Immunomic Therapeutics, Inc.
  • IOVANCE Biotherapeutics, Inc.
  • Medigene AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Neon Therapeutics, Inc.
  • Nykode Therapeutics
  • Pfizer Inc.
  • Precision Biologics
  • Valo Therapeutics Ltd

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.24 Billion
Compound Annual Growth Rate16.1%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Neoantigen Targeted Therapies Market Report 2025 - Product Image

Neoantigen Targeted Therapies Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Pancreatic Cancer Precision Medicine Market Size, Share & Trends Analysis Report by Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations), Diagnostic Technology, and Region with Growth Forecasts, 2025-2030 - Product Image

Pancreatic Cancer Precision Medicine Market Size, Share & Trends Analysis Report by Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations), Diagnostic Technology, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2025 - Product Image

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2025

  • Report
  • 175 Pages
  • Global
From
DLL3 Targeted Therapies Market, Approved Drugs Dosage, Pricing & Clinical Trials Insight 2025 - Product Image

DLL3 Targeted Therapies Market, Approved Drugs Dosage, Pricing & Clinical Trials Insight 2025

  • Report
  • 140 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.